HBC Hofseth Biocare

Hofseth Biocare ASA: CHAIR KRISTIN FJELLBY GRUNG STEPS DOWN

Hofseth Biocare ASA: CHAIR KRISTIN FJELLBY GRUNG STEPS DOWN

Kristin Fjellby Grung, Chair of the Board of Hofseth BioCare ASA, has informed the Board of Directors that she will resign from the position on 31 March 2024, as she will assume a position as judge in the District Court of Møre and Romsdal and will therefore not be able to continue to serve in the position as Chair of the Board.

Grung has been a member of the Board of Directors since December 2020, and assumed the position as Chair in April 2022. The Board would like to thank Grung for her services for Hofseth BioCare in this period.

Appointment of a new Chair of the Board will be proposed to the Company's annual general meeting, to be held on 10 May 2024. In the interim period, Roger Hofseth will function as the Chair of the Board of Directors.

For further information, please contact:

Jon Olav Ødegård, CEO at HBC

Phone:  966

E-mail:

About Hofseth BioCare ASA:

HBC is a Norwegian consumer and pet health ingredient supplier and an incubator for new pharmaceutical drug leads.  Research is ongoing to identify the individual elements within its ingredients that modulate inflammation and the immune response with pre-clinical studies ongoing in multiple clinics and university research labs. Lead clinical and pre-clinical candidates are focused on developing an oral treatment for inflammatory disease driven by eosinophils (a type of white blood cell). Clinical trial work with the oil is ongoing to ameliorate lung inflammation in eosinophilic asthma and COPD ("smokers lung").

Other leads are focused on using the Company's bioactive peptides as a Medical Food   for the protection of the Gastro- Intestinal (GI) system against inflammation (including ulcerative colitis and the orphan condition necrotizing enterocolitis). The Company is founded on the core values of sustainability, optimal   utilization of natural resources and full traceability.  Through innovative and patent protected hydrolysis technology, HBC can preserve the quality of the lipids, proteins and calcium from fresh salmon off-cuts.

HBC's headquarters are in Ålesund, Norway with offices in Oslo, London, Zürich, New Jersey and Palo Alto, CA.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.



EN
14/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Hofseth Biocare

 PRESS RELEASE

Hofseth BioCare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING

Hofseth BioCare ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING Reference is made to the stock exchange announcement by Hofseth BioCare ASA ("HBC" or the "Company") on 27 October 2025 regarding (i) the completion of a private placement (the "Private Placement") of new shares in the Company the "Offer Shares"), the completion of which by delivery of Offer Shares in tranche 2 (the "T2 Offer Shares") is subject to, among other things, an extraordinary general meeting (the "EGM") resolving to issue the T2 Offer Shares in the Private Placement and (ii) a potential subsequent repair offering which i...

 PRESS RELEASE

Hofseth BioCare ASA: Mandatory Notification of Trade

Hofseth BioCare ASA: Mandatory Notification of Trade Reference is made to the stock exchange announcement by Hofseth Biocare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placement (the "Private Placement") of new shares in the Company. In the Private Placement, Hofseth International AS was allocated 28,666,666 new shares at the subscription price of NOK 1.80. Please refer to the attached notification form for further information. This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19. For furth...

 PRESS RELEASE

Ex. Subsequent Offering Today

Ex. Subsequent Offering Today NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcement by Hofseth Biocare ASA ("HBC" or the "Company") on 27 October 2025 relating to a contemplated subsequent offering of up to 16,666,666 new shares directed towards certain eligible shareholders...

 PRESS RELEASE

Hofseth BioCare ASA: Key Information Relating to Subsequent Offering

Hofseth BioCare ASA: Key Information Relating to Subsequent Offering NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Reference is made to the stock exchange announcement by Hofseth BioCare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placement (the "Private Placement") of new shares i...

 PRESS RELEASE

Hofseth BioCare ASA: Disclosures of Large Shareholdings

Hofseth BioCare ASA: Disclosures of Large Shareholdings Reference is made to the stock exchange announcement by Hofseth BioCare ASA ("HBC" or the "Company") on 27 October 2025 regarding completion of a private placement (the "Private Placement") of new shares in the Company. The following shareholders of the Company have, on 27 October 2025, been allocated new shares in the Private Placement which implies that their holdings have surpassed a notifiable threshold: Guy Urquhart have subscribed for 55,444,444 new shares in the Private Placement. Following this, Guy Urquhart holds 55,444,444...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch